From: pharmavoice.com The use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes. Most pharmaceutical companies and contract research organizations have adopted technology solutions, including electronic data capture solutions and clinical trial management systems to increase efficiencies, reduce costs, and improve the patient experience. These solutions have been instrumental in improving clinical …
Education About Breast Cancer Treatment Options
View PostUT Southwestern Researchers find evidence a cancer drug may be extended to many more patients
Source: UT Southwestern Medical Center From: PR Newswire A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers. The new study also revealed a potential biomarker indicating when …
Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations
From: mdanderson.org FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, according to an international Phase II trial led by The University of …
AI for Breast Cancer Diagnosis: The First FDA Cleared System Is Here
By: Mariam Haider From: parentology.com From apps that scan for sun damage to devices that restore eyesight, Artificial Intelligence (AI) is changing how we approach healthcare. The latest in this ever-growing list: AI for breast cancer diagnosis. QuantX, created by Paragon Biosciences and Qlarity Imaging, is an AI-based breast cancer diagnosis system. It is the first ever cleared by the …
First-in-Class Drug Preserves Blood Counts During Chemotherapy for Lung Cancer
By: Beth Fand Incollingo From: curetoday.com Given with each dose of chemotherapy, administration of trilaciclib may temporarily put bone marrow to sleep, helping to prevent fevers, infections and hospital stays in patients with small cell lung cancer, according to study findings presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Side effects from chemotherapy often include nausea, …
Unlocking therapies for hard-to-treat lung cancers
Source: Salk Institute for Biological Studies From: prnewswire.com Salk scientists find that diabetes drug candidates may work against types of non-small-cell lung cancers Around 85 percent of lung cancers are classified as non-small-cell lung cancers, or NSCLCs. Some patients with these cancers can be treated with targeted genetic therapies, and some benefit from immunotherapies—but the vast majority of NSCLC patients …
George Mason University breast cancer treatment patent licensed by Targeted Pharmaceuticals
Source: George Mason University From: eurekalert.org A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders. The patent, secured by faculty members of George …
The FDA Requests Allergan Voluntarily Recall Natrelle BIOCELL Textured Breast Implants and Tissue Expanders from the Market to Protect Patients
From: fda.gov To protect individuals from the increased risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), associated with Allergan BIOCELL textured breast implants, the Food and Drug Administration (FDA) requested that Allergan recall its BIOCELL textured breast implants and tissue expanders. Allergan agreed and is removing these products from the global market. The FDA requested that Allergan recall all …
How TransCelerate is digitalizing patient engagement in clinical trials
By: Andrew Burrows From: knect365.com Patient-facing digital technologies have the potential to serve a variety of functions in clinical trials, such as capturing clinical endpoints, engaging patients, and facilitating remote study conduct. However, these technologies are not yet accepted as mainstream research tools, and the opportunities, challenges, and facilitators associated with their implementation in clinical trials have not been fully …